MIKAO MAYAMA

727 citations
35 papers · 571 indexed · h-index 14

MIKAO MAYAMA

35 papers receiving 515 citations

Peers

MIKAO MAYAMA
Comparison fields: 5 of 72
  • Molecular Medicine 94
  • Pharmacology 258
  • Microbiology 77
  • Toxicology 24
  • Biotechnology 60
Replace Kei-Ichi Fujisawa with:
Kei-Ichi Fujisawa United Kingdom
B. CAVALLERI Italy
J. BLUMBACH India
HIROSHI HINOO Japan
JOSEPH A. MARQUEZ United States
R. NAGARAJAN United States
Pacifico A. Principe Malaysia
TAKAO NOTO United States
Marlene L. Rathnum Malaysia
P. J. Petersen United States
MIKAO MAYAMA relative to Kei-Ichi Fujisawa United Kingdom Kei-Ichi Fujisawa's profile →
Citations per field
00.5×3.8×
Kei-Ichi Fujisawa · 1×
Citations per year

Countries citing papers authored by MIKAO MAYAMA

Since Specialization
Citations

This map shows the geographic impact of MIKAO MAYAMA's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by MIKAO MAYAMA with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites MIKAO MAYAMA more than expected).

Fields of papers citing papers by MIKAO MAYAMA

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by MIKAO MAYAMA. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by MIKAO MAYAMA. The network helps show where MIKAO MAYAMA may publish in the future.

Co-authorship network

The 25 scholars most cited alongside MIKAO MAYAMA, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with MIKAO MAYAMA Line = papers co-authored together MIKAO MAYAMA links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 198221
2 19823
3 19816
4 198138
5 198064
6 19806
7
Studies on antibiotics from the genus Bacillus. VIII. Isolation of three new antibiotics, thiocillins I, II and III, related to micrococcin P.:STUDIES ON ANTIBIOTICS FROM THE GENUS BACILLUS . VIII
19768
8 19762
9 19763
10 197610
11 197638
12 19757
13 19759
14 197010
15 197013
16 19707
17 19684
18 19688
19 19654
20
Toyocamycin, a new anti-candida antibiotics.
195637

About MIKAO MAYAMA

MIKAO MAYAMA is a scholar working on Microbiology, Microbiology and Pharmacology, having authored 35 papers that have together received 571 indexed citations. Recurring topics across this work include Microbial Natural Products and Biosynthesis (16 papers), Antimicrobial Peptides and Activities (12 papers), Chemical Synthesis and Analysis (8 papers), Antibiotic Resistance in Bacteria (5 papers), Machine Learning in Bioinformatics (4 papers), Biopolymer Synthesis and Applications (4 papers), Carbohydrate Chemistry and Synthesis (3 papers) and Probiotics and Fermented Foods (3 papers). The work is most often cited by research in Molecular Medicine (94 citations), Pharmacology (258 citations) and Microbiology (77 citations). MIKAO MAYAMA has collaborated with scholars based in Japan and United States. Frequent co-authors include JUN''ICHI SHOJI, SHINZO MATSUURA, Yoshiharu Wakisaka, Kenzo Koizumi, Yoshimi Kawamura, HIROSHI HINOO, Tadashi Yoshida, Koichi Matsumoto, Shōgo Kuwahara and Naoki Tsuji.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026